The O’Reilly Lab has received significant financial support from the National Institutes of Health and other sources.
- NIH 1 R15 GM140412-01 AREA Grant: $340,871
- Development of allosteric dihydrofolate reductase inhibitors: exploration of a novel inhibitory mechanism for a validated antibiotic target
- March 2021 –> February 2024
- WiSys Applied Research Technology Advancement Grant: $46,891
- Discovery of emmacin related dihydropyrimidine analogs as dihydrofolate reductase inhibitors with narrow and broad-spectrum antibiotic activity
- June 2019 –> August 2020
- WiSys Spark Grant: $9,785
- Characterization of the enantiospecific antimicrobial activity of emmacin-related substituted dihydropyrimidines
- June 2019 –> December 2019